Back to top

Hemab Therapeutics Holdings, Inc. (COAG) Gets a Buy from Wedbush

Wedbush analyst David Nierengarten maintained a Buy rating on Hemab Therapeutics Holdings, Inc. today and set a price target of $64.00. According t...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE: